Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is experiencing positive growth potential through strategic partnerships in the pharmaco-epigenetics space, which may lead to increased revenue and wider adoption of its biomarker technology. The successful validation of its Nu.Q Lung Cancer Test is seen as a pivotal moment that could enhance the company's attractiveness to prospective partners within the diagnostics and pharmaceutical sectors. Additionally, the company's automated systems for veterinary diagnostics, coupled with a robust presence in Japan, suggest a significant opportunity to expand its market footprint further, enhancing overall revenue prospects.

Bears say

VolitionRX Ltd is currently engaged in research aimed at reducing high false-positive rates from low-dose computed tomography (LDCT) screenings for pulmonary nodules, which may not resolve its fundamental challenges in market penetration and competitive positioning. The reliance on its Nucleosomics platform necessitates significant investment in clinical validation and regulatory approvals, which could further strain financial resources amid an already competitive diagnostics landscape. Additionally, the potential for unnecessary invasive procedures linked to its testing methods raises concerns about patient adoption and long-term profitability, impacting overall investor confidence.

Volitionrx Limited (VNRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.